Parstatin suppresses ocular neovascularization and inflammation

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 11, 2010, Pages 5825-5832

  Huang, Hu ^a   Vasilakis, Panagiotis ^b   Zhong, Xiufeng ^a   Shen, Ji Kui ^a   Geronatsiou, Katerina ^b   Papadaki, Helen ^b   Maragoudakis, Michael E ^b   Gartaganis, Sotirios P ^b   Vinores, Stanley A ^a   Tsopanoglou, Nikos E ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; PARSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRUCH MEMBRANE; CONTROLLED STUDY; CORNEA STROMA; DRUG EFFICACY; DRUG POTENCY; LEUKOSTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; RETINA ISCHEMIA; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; INTRAVITREAL INJECTIONS; KERATITIS; LEUKOSTASIS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PAR-1; RETINAL DISEASES; RETINAL NEOVASCULARIZATION;

EID: 79956008665     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5576     Document Type: Article

References (40)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
2. Folkman J. Angiogenesis. Ann Rev Med. 2006;57:1-18.
3. Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med. 2009;9:973-981.
4. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104: 264-302.
5. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis, and vascular biology. J Thromb Haemost. 2005;3:1800-1814.
6. Tsopanoglou NE, Maragoudakis ME. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. Semin Thromb Hemost. 2007;33:680-687.
7. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor action. Cell. 1991;64:841-848.
8. Zania P, Gourni D, Aplin AC, et al. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J Pharmacol Exp Ther. 2009;328:378-389.
9. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641-1646.
10. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
11. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
12. Shen J, Xie B, Dong A, et al. In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels. Invest Ophthalmol Vis Sci. 2007;48:4335-4341.
13. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygen- induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009; 4:1565-1573.
14. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531-535.
15. Vinores SA, Xiao W-H, Shen J, Campochiaro PA. TNF[1] is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol. 2007;182:73-79.
16. Ross LL, Danehower SC, Proia AD, et al. Coordinated activation of corneal wound response genes in vivo as observed by in situ hybridization. Exp Eye Res. 1995;61:435-450.
17. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci. 2003;44:1837-1842.
18. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model ofretinal neovascularization. Invest Ophthalmol Vis Sci. 2002;43: 260-266.
19. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
20. Zhang SX, Ma JX. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007;26:1-37.
21. Williams R, Airey M, Baxter H, et al. Epidemiology of diabetic retinopathy and macular oedema: a systemic review. Eye. 2004; 18:963-983.
22. Drack A. Retinopathy of prematurity. Adv Pediatr. 2006;53:211-226.
23. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
24. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
25. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
26. Vinores SA. Anti-VEGF therapy for ocular vascular diseases. In: Maragoudakis M, Papadimitriou E, eds. Angiogenesis: Basic Science and Clinical Applications. Kerala, India: Transworld Research Network; 2007;28:467-482.
27. Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and ocular neovascularization. Cell. 2010;141:178-190.
28. Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, Goldenberg-Cohen N. Effect of subconjunctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis. 2009;15:2326-2338.
29. Aiello LP. Vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1997;38:1647-1652.
30. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation- related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
31. Ozaki H, Seo M-S, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signalling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:679-707.
32. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
33. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2006;113:1-12.
34. Ozaki H, Okamoto N, Ortega S, et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal Neovascularization. Am J Pathol. 1998;153:757-765.
35. Yamada H, Yamada E, Kwak N, et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol. 2000;185:135-142.
36. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006;51:137-152.
37. Lima e Silva R, Shen J, Hackett SF, et al. The SDF-1/CXCR4 ligand/ receptor pair is an important contributor to several types of ocular neovascularization. FASEB J. 2007;21:3219-3230.
38. Noda K, Miyahara S, Nakazawa T, et al. Vascular adhesion protein-1 blockage suppresses choroidal neovascularization. FASEB J. 2008; 22:2928-2935.
39. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033-1036.
40. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.